Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.
BIRC5
breast cancer
molecular signature
survival probability
survivin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 May 2021
04 May 2021
Historique:
received:
17
03
2021
revised:
28
04
2021
accepted:
01
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Breast cancer (BC) histological and molecular classifications significantly improved the treatment strategy and prognosis. Inhibitor of apoptosis BIRC5/survivin is often overexpressed in cancers, however, indications of its importance in BC are inconsistent. We integrate BIRC5 protein and mRNA measures with clinical associates and long-term outcome in three independent cohorts Protein levels of BIRC5 were measured in primary lysates of 845 patients of the West Swedish BC cohort (VGR-BC) and linked to 5- and 27-years survival. The results were externally validated in transcriptomic data from METABRIC and SCAN-B cohorts. Survival analysis showed that high levels of BIRC5 were consistently associated with a poor probability of 5-year overall survival. High BIRC5 in VGR-BC contributed negatively to the disease-specific survival at 5 and 27 years. Subsets with different status by ER (estrogen receptor) expression and presence of nodal metastasis supported independent association of high BIRC5 with poor prognosis in all cohorts. In METABRIC and SCAN-B cohorts, high levels of BIRC5 mRNA were associated with the basal-like and luminal B molecular BC subtypes and with increasing histologic grade. BIRC5 is a sensitive survival marker that acts independent of ER and nodal status, and its levels need to be considered when making treatment decisions.
Identifiants
pubmed: 34064473
pii: cancers13092209
doi: 10.3390/cancers13092209
pmc: PMC8125570
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Swedish Research Council
ID : 521-2017-03025 (MB)
Organisme : Swedish Cancer Society
ID : 2019/0081 (PK)
Organisme : Swedish Association against Rheumatism
ID : R-566961 (MB)
Organisme : King Gustav V Jubilee Clinic Foundation
ID : 2019:248 (PK)
Organisme : King Gustaf V:s 80-year Foundation
ID : MB
Organisme : Regional agreement on medical training and clinical research between the Western Götaland county council and the University of Gothenburg
ID : ALFGBG-717681 (MB); ALFGBG-716711 (PK)
Organisme : University of Gothenburg, Walter Andersons fond for scientific research, Southern Älvsborg Hospital, Borås, Sweden
ID : AFB and ZE
Références
Carcinogenesis. 2013 Sep;34(9):2137-44
pubmed: 23640047
Ann Oncol. 2015 Jun;26(6):1149-1154
pubmed: 25839671
NPJ Breast Cancer. 2020 May 12;6:17
pubmed: 32411819
Ont Health Technol Assess Ser. 2020 Mar 6;20(10):1-234
pubmed: 32284770
Cancer Res. 1984 Jun;44(6):2348-51
pubmed: 6722773
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):635-40
pubmed: 11149963
Arch Pathol Lab Med. 2000 Jul;124(7):1026-33
pubmed: 10888779
Cancer Immunol Immunother. 2010 Aug;59(8):1211-21
pubmed: 20422411
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Tumour Biol. 2013 Aug;34(4):2053-62
pubmed: 23690235
J Natl Cancer Inst. 2012 Feb 22;104(4):311-25
pubmed: 22262870
Mol Biol Rep. 2018 Dec;45(6):2185-2192
pubmed: 30225582
Breast Cancer Res Treat. 2012 Feb;131(3):765-75
pubmed: 21452023
Breast J. 2014 Sep-Oct;20(5):514-24
pubmed: 25041354
Breast Cancer Res Treat. 2018 Apr;168(3):613-623
pubmed: 29330624
Surg Oncol Clin N Am. 2018 Jan;27(1):95-120
pubmed: 29132568
Med Oncol. 2013 Jun;30(2):523
pubmed: 23468220
Breast Cancer Res Treat. 2016 Oct;159(3):499-511
pubmed: 27592112
BMC Cancer. 2014 Mar 12;14:176
pubmed: 24620748
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
pubmed: 12829800
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Breast Cancer Res. 2010;12(4):207
pubmed: 20804570
Int J Cancer. 2019 Feb 15;144(4):697-706
pubmed: 30144028
NPJ Breast Cancer. 2019 Aug 2;5:21
pubmed: 31396557
Breast. 2019 Nov;48 Suppl 1:S7-S20
pubmed: 31839166
Br J Cancer. 2007 Feb 26;96(4):639-45
pubmed: 17285125
Int J Oncol. 2011 Sep;39(3):569-75
pubmed: 21674125
Genome Med. 2015 Feb 02;7(1):20
pubmed: 25722745
Oncotarget. 2017 Jun 20;8(25):41282-41293
pubmed: 28476037
Cancer Res. 2008 Jul 1;68(13):5273-81
pubmed: 18593928
J Pathol Transl Med. 2017 Jan;51(1):17-23
pubmed: 27989099
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Einstein (Sao Paulo). 2018;16(1):eAO4065
pubmed: 29694611
Oncotarget. 2017 Apr 18;8(16):26122-26128
pubmed: 28412725
Am J Cancer Res. 2015 Sep 15;5(10):2929-43
pubmed: 26693050
J Cancer Res Clin Oncol. 2020 Aug;146(8):2041-2049
pubmed: 32472445
Database (Oxford). 2013 Jan 15;2013:bas060
pubmed: 23325629
Ann Oncol. 2019 Jul 1;30(7):1181
pubmed: 30624592
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Breast Cancer Res. 2014 May 30;16(3):R55
pubmed: 24886669
Oncologist. 2006 Sep;11(8):868-77
pubmed: 16951390
Cancer Cell Int. 2016 Jun 23;16:49
pubmed: 27340370
Breast Cancer Res Treat. 2015 Jan;149(1):171-9
pubmed: 25547219
Neoplasia. 2015 Mar;17(3):317-28
pubmed: 25810016
Br J Cancer. 2003 Apr 7;88(7):1077-83
pubmed: 12671708
Clin Breast Cancer. 2011 Apr;11(2):129-34
pubmed: 21569999
Arthritis Res Ther. 2005;7(2):R349-58
pubmed: 15743483
BMC Cancer. 2010 Nov 23;10:639
pubmed: 21092276
Int J Oncol. 2002 Apr;20(4):791-6
pubmed: 11894126
Breast Cancer Res. 2008;10(6):R97
pubmed: 19025652
Acta Oncol. 2019 Jan;58(1):45-51
pubmed: 30513223
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705
pubmed: 32555420
J Oncol. 2019 Jul 28;2019:3483192
pubmed: 31467536
Acta Oncol. 2019 Feb;58(2):154-161
pubmed: 30351173
Breast Cancer Res. 2019 Dec 19;21(1):147
pubmed: 31856876
Cancer Med. 2020 Oct;9(20):7672-7685
pubmed: 32841536
Rev Assoc Med Bras (1992). 2019 Jul 22;65(6):893-901
pubmed: 31340322
Oncoimmunology. 2017 Jan 19;6(3):e1282590
pubmed: 28405507
Eur J Cancer. 2017 Apr;75:284-298
pubmed: 28259011
Surg Oncol. 2012 Jun;21(2):125-31
pubmed: 21334875
Cancer Immunol Immunother. 2012 Nov;61(11):2091-103
pubmed: 22565484
Clin Cancer Res. 2008 May 1;14(9):2681-9
pubmed: 18451232
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Cell Sci. 2019 Apr 4;132(7):
pubmed: 30948431
Mol Med Rep. 2014 Feb;9(2):614-20
pubmed: 24317109
J Thorac Dis. 2010 Jun;2(2):100-10
pubmed: 22263027
PLoS One. 2016 Oct 20;11(10):e0165117
pubmed: 27764228
Neoplasma. 2016;63(1):133-40
pubmed: 26639243